Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT04003610
Title	Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)
Recruitment	Terminated
Gender	both
Phase	Phase II
Variant Requirements	Yes
Sponsors	Incyte Corporation
Indications	transitional cell carcinoma
Therapies	Pembrolizumab + Pemigatinib Pembrolizumab Carboplatin + Gemcitabine Pemigatinib
Age Groups:	senior \| adult
Covered Countries	USA \| ITA \| GBR \| FRA \| ESP \| DEU \| CAN \| BEL \| AUT